Date: October 01, 2026

Acquisition Details

Jagsonpal Pharmaceuticals Limited has consummated the acquisition of the Wellness Portfolio from Group Pharmaceuticals Limited effective October 01, 2026, following the fulfilment of Conditions Precedent under the Business Transfer Agreement signed on September 23, 2026.

Transaction Structure

  • Upfront Consideration: Approximately ₹23.7 crore
  • Maximum Additional Consideration: Approximately ₹23.0 crore linked to FY28 sales performance
  • Total Potential Consideration: Up to ₹46.7 crore

Acquired Business Profile

  • FY26 Revenue: ₹24.6 crore
  • Geographic Presence: 6 states
  • Key Brands: 2 brands (6 SKUs)
  • Field Force: Approximately 125 medical representatives
  • Doctor Network: Approximately 30,000 doctors

Strategic Rationale

  • Expands Rx-brand portfolio into consumer wellness segment
  • Strengthens market presence and doctor reach
  • Creates a larger platform for future growth
  • Margin accretive to existing operations
  • Complementary portfolio that enables cross-selling opportunities

Value Creation Synergies

Expanded Business Reach

  • Combined Doctor Network: 54,000+ doctors (Jagsonpal existing: 190,000+)
  • Combined Field Force: 1,000+ medical representatives (Jagsonpal existing: 1,000+)
  • Geographic Presence: Pan-India coverage enhanced with focus on MP, UP, Karnataka

Synergy Opportunities

  • Cross-sell acquired brands through JPL's existing field force to drive incremental volumes
  • Cross-sell JPL brands through the expanded doctor base
  • Deepened penetration in key markets (MP, UP, Karnataka)
  • Cost synergy across supply chain including procurement and distribution

Financial Context

Q1FY27 Performance Highlights

  • Revenue Growth: 9% year-over-year
  • Operating EBITDA Growth: 21% year-over-year
  • PAT Expansion: 22% year-over-year
  • Cash Balance: Approximately ₹170 crore as of Q1FY27

Acquisition Strategy

The acquisition represents part of Jagsonpal's disciplined M&A approach:

  • May 2024: Yash Pharma business acquisition expanded portfolio to Dermatology
  • July 2026: Aequitas Healthcare acquisition expanded hospital and institutional reach
  • October 2026: Group Pharmaceuticals adds consumer wellness pillar

Integration Track Record

  • Yash Pharma business fully integrated with EBITDA margin improved from ~10% at acquisition to ~22% at corporate level
  • Aequitas Healthcare targeting ~₹10 crore EBITDA in medium term from negligible levels today

Corporate Overview

Business Metrics (Current)

  • Doctors: 190,000+
  • Field Force: 1,000+ medical representatives
  • Geographic Presence: Pan-India across 4,000+ towns and cities
  • Distributors: 1,200+
  • Hospital Coverage: 1,000+ hospitals
  • Stockists: ~3,500

Therapeutic Strengths

  • Gynecology: Ranked 7th in CVM, reaching ~90% of gynecologists nationwide
  • Orthopedics: Ranked 2nd in CVM, reaching ~80% of orthopedists
  • Pediatrics: Ranked 17th in CVM, maintaining regular connect with 9,700 pediatricians
  • Dermatology: Ranked 30th in CVM, regular connect with ~4,500 dermatologists

Strategic Pillars

  • Innovation - Niche Molecules, Dominant Market Share
  • Large, well-trained workforce of 1,000+ Medical Representatives
  • Lean Operations: Asset Light Model
  • Inorganic Growth Powered by Strategic Acquisition

Mission 2028

The company is targeting becoming an INR 500 crore organization by 2028, with this acquisition representing a significant step toward that goal.

Investor Relations Contact

Soumya Chhajed